SCHEMBL1722128

SCHEMBL1722128

OB(O)C1CC1c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 10/20 0.48
MAOA P21397 7/20 0.48
HTR2C P28335 7/20 0.48
KDM1A O60341 5/20 0.48
CYP2C19 P33261 4/20 0.48
CYP2B6 P20813 3/20 0.48
CYP1A2 P05177 2/20 0.48
CYP2D6 P10635 2/20 0.48
CYP2C9 P11712 2/20 0.48
LMNA P02545 2/20 0.48
TAAR1 Q96RJ0 2/20 0.48
CYP3A4 P08684 1/20 0.48
HTR1A P08908 1/20 0.48
ADRA2A P08913 1/20 0.48
CYP2A6 P11509 1/20 0.48
SLC6A2 P23975 1/20 0.48
ADRA1A P35348 1/20 0.48
DRD3 P35462 1/20 0.48
SLC6A3 Q01959 1/20 0.48
KCNH2 Q12809 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954166 1.00 MAOB (0.48) MAOBMAOAHTR2CKDM1ACYP2C19
SCHEMBL1781688 1.00 MAOB (0.48) MAOBMAOAHTR2CKDM1ACYP2C19
SCHEMBL29953893 0.78 KDM1A (0.52) HTR2CKDM1ASLC6A2SLC6A3HTR2B
SCHEMBL29954843 0.78 HTR2A (0.44) HTR2CCYP2C19CYP1A2CYP2C9CYP3A4
SCHEMBL9817364 0.77 MEN1 (0.50) MAOBMAOAHTR2CKDM1ACYP2C19
SCHEMBL10489495 0.77 MEN1 (0.50) MAOBMAOAHTR2CKDM1ACYP2C19
SCHEMBL9817367 0.77 MEN1 (0.50) MAOBMAOAHTR2CKDM1ACYP2C19
SCHEMBL29957110 0.77 CYP2A6 (0.58) KDM1ACYP2A6
SCHEMBL29954593 0.77 HTR2A (0.51) HTR2CKDM1ASLC6A2SLC6A3RCOR1
SCHEMBL149599 0.77 KDM1A (0.58) HTR2CKDM1ASLC6A3RCOR1HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441726-B2 Compounds and uses thereof FOGHORN THERAPEUTICS, INC. (US) 2025-10-14 US disclosed
US-12110294-B2 CD73 compounds GILEAD SCIENCES, INC. (US) 2024-10-08 US disclosed
CN-115297861-B Compounds and uses thereof 福宏治疗公司 2024-07-12 CN disclosed
US-20240043427-A1 CD73 COMPOUNDS GILEAD SCIENCES, INC. 2024-02-08 US disclosed
US-11793821-B2 Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors MERCK SHARP & DOHME LLC (US) 2023-10-24 US disclosed
US-11793821-B2 Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors MERCK SHARP & DOHME LLC (US) 2023-10-24 US disclosed
US-11793821-B2 Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors MERCK SHARP & DOHME LLC (US) 2023-10-24 US disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
US-20110319439-A1 AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY 2011-12-29 US disclosed
US-20110319449-A1 PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY 2011-12-29 US disclosed
US-20110319439-A1 AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY 2011-12-29 US disclosed
US-20110118282-A1 Soluble Guanylate Cyclase Activators MERCK SHARP & DOHME LLC 2011-05-19 US disclosed
WO-2010104818-A1 AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-09-16 WO disclosed
US-7728142-B2 3-methanesulfonylquinolines as GABAB enhancers HOFFMANN-LA ROCHE INC. (US) 2010-06-01 US disclosed
US-20090209556-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS MERCK SHARP & DOHME CORP. 2009-08-20 US disclosed
EP-1893560-A2 3-METHANESULFONYLQUINOLINES AS GABA-B ENHANCERS F. Hoffmann-Roche AG (CH) 2008-03-05 EP disclosed
WO-2006128802-A2 3-METHANESULFONYLQUINOLINES AS GABA-B ENHANCERS F. HOFFMANN-LA ROCHE AG (CH) 2006-12-07 WO disclosed
US-20060276469-A1 such as 3-Methanesulfonyl-2-methyl-4-phenyl-6-trifluoromethoxy-quinoline for treatment of CNS disorders such as anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy HOFFMANN-LA ROCHE INC. 2006-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11793821-B2 Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors CHRNA7, CHRNA6, CHRNA5 MAOB 201/4885MAOA 152/4885HTR2C 83/4885
US-20110319449-A1 PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS MCHR1, MCHR2, MC1R MAOB 183/4885MAOA 217/4885HTR2C 136/4885
US-20240043427-A1 CD73 COMPOUNDS ENTPD5, ENTPD1, NT5E MAOB 1036/4885MAOA 1171/4885HTR2C 1699/4885
US-20060276469-A1 such as 3-Methanesulfonyl-2-methyl-4-phenyl-6-trifluoromethoxy-quinoline for treatment of CNS disorders such as anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy GABBR1, GABRR3, GABRR2 MAOB 1148/4885MAOA 2057/4885HTR2C 62/4885
US-12441726-B2 Compounds and uses thereof VHL, CLN6, TFEB MAOB 975/4885MAOA 2223/4885HTR2C 3674/4885
US-12110294-B2 CD73 compounds ENTPD5, ENTPD1, NT5E MAOB 778/4885MAOA 1004/4885HTR2C 2034/4885
US-20110319439-A1 AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS MCHR1, MCHR2, MC1R MAOB 142/4885MAOA 154/4885HTR2C 196/4885
US-20110118282-A1 Soluble Guanylate Cyclase Activators GUCY1B1, GUCY1A2, GUCY1A1 MAOB 606/4885MAOA 609/4885HTR2C 2306/4885
US-20090209556-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS GUCY1B1, GUCY1A2, GUCY1A1 MAOB 606/4885MAOA 609/4885HTR2C 2306/4885
US-20230145003-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB MAOB 975/4885MAOA 2223/4885HTR2C 3674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.